DAPA is an insulin-independent antidiabetic drug that acts as a SGLT2 inhibitor and aims to control hyperglycaemia via providing glucose excretion from the kidney through a mechanism different to that of other antidiabetic drug groups. The gene discussed is INS; the disease is Hyperglycemia.